- Mexico is classified as the second country with the highest prevalence of this condition in all of Latin America.
- Insulin glargine authorized by Cofepris is a biocomparable biotechnological for the treatment of diabetes mellitus.
- In addition, a clinical trial was endorsed for patients with previously untreated locally advanced or metastatic urothelial cancer, commonly known as bladder cancer.
The Diabetes mellitus is one of the fastest growing diseases in Mexico and to help patients the Federal Commission for Protection against Sanitary Risks (Cofepris) authorized a new insulin glargine molecule. In this way, the options available for the treatment of affected people are expanded.
First of all it is necessary to understand the condition. According to the World Health Organization (WHO), diabetes is a A chronic disease that occurs when the pancreas does not secrete enough insulin or when the body does not effectively use the insulin it produces.
However, based on world statistics, it is estimated that About 8.5% of those over the age of 18 have diabetes. Although one of the problems is that not all have been diagnosed because many have the condition but are unaware of it due to the lack of regular medical check-ups.
For its part, the platform HelloSafe states that Mexico is the country with the second highest prevalence of diabetes in all of Latin America. While at present it is already one of the main causes of death.
To deal with the current problems and increase the available treatments, the Cofepris authorized a new insulin glargine molecule against diabetes mellitus. The information was disclosed in the most recent fortnightly therapeutic expansion report, which mentions that 171 new health supplies were endorsed.
#Cofepris authorizes 171 health supplies; highlights clinical trial for treatment of bladder cancer. #FortnightlyReportOnTherapeuticExpansion
💊https://t.co/tp1YlZ7vcC pic.twitter.com/k7AbT4tQpj
— COFEPRIS (@COFEPRIS) September 7, 2023
Of these new registries, 10 correspond to clinical trials, including one for the treatment of patients with urothelial cancercommonly known as previously untreated locally advanced or metastatic bladder cancer, and who are not eligible for platinum-based chemotherapy treatment.
Clinical trials are investigations that are carried out in humans to find health supplies that are effective, safe, efficient in the diagnosis, treatment and/or prevention of diseases.
Three new molecules were also authorized: mesalazine, for the treatment of ulcerative colitis; azelastine/mometasone, for the care of allergic rhinitis in people over 12 years of age; and abrocitinib treatment of moderate to severe atopic dermatitis. In addition, insulin glargine, a biocomparable biotechnological for the treatment of diabetes mellitus, and 36 generics for a total of 40 new drug health registrations.
The latest report also reports the authorization of 121 new medical devices, of which 59 are for medical care. Among them stands out artificial urinary sphincter, a retrograde femoral nail, a coronary stent, and an intravascular heat exchange catheter.
Among these inputs there are also 38 new medical equipment, such as surgical lasers, X-ray equipment and video endoscopes, in addition to 24 new devices for clinical diagnoses.
Also read:
Diabetes in Mexico: Only 1 in 10 people undergo diagnostic tests
Mexico is the second country with the highest prevalence of diabetes in Latin America
Cofepris facilitates the approval of biotechnological and biosimilar medicines in Mexico